Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zidovudine + Lamivudine vs d4T vs Zidovudine + d4T in HIV-Infected Patients
NCT00001067Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised trial in human immunodeficiency virus infection (HIV) comparing Stavudine (d4T) alone, Zidovudine (AZT) alone and Combination (AZT + d4T -> AZT + d4T + 3TC) (3 arms). Primary endpoints: Magnitude of HIV RNA over time at 48 weeks, Immunologic Effects (CD4 Cell Count) at 48 weeks and 1 more. Status: completed.
02
Drugs
stavudinezidovudinelamivudine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00001067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001067.